Home > Haematology > EHA 2021 > Lymphoma > Promising chemo-free treatment options in r/r DLBCL

Promising chemo-free treatment options in r/r DLBCL

Presented By
Prof. Marco Ladetto, University del Piemonte Orientale, Italy
Conference
EHA 2021
Trial
LOTIS-2
Several novel agents and combinations are under development as alternatives to chemotherapy treatment in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). These new agents include novel antibodies, CAR T-cell therapy, checkpoint inhibitors, immunotoxins, PI3K inhibitors, novel kinase inhibitors, BiTE, Bcl-2 inhibitors, and BTK inhibitors [1]. The poor outcomes of chemotherapy in patients with r/r DLBCL create a major unmet medical need for alternative treatment regimes. This is true for patients either eligible or ineligible for transplantation. For example, rituximab + gemcitabine and oxaliplatin (R-GemOx) in r/r DLBCL patients ineligible for autologous transplantation demonstrated a median progression free-survival time of 5 months and a median overall survival of only 10 months [2]. Prof. Marco Ladetto (University del Piemonte Orientale, Italy) discussed the use of non-chemotherapeutic agents in transplant-ineligible r/r DLBCL. N...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on